Ofatumumab: a second generation anti-CD20 monoclonal antibody in chronic lymphocytic leukemia


https://doi.org/10.4081/hmr.v3i3.583
Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 148
PDF: 325
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The successful use of monoclonal antibodies (mAb) in the treatment of human disease has steadily been growing the last decade. Rituximab, a humanmouse chimeric anti-CD20 antibody, was the first mAb for antilymphoma therapy approved. It was introduced as monotherapy and is now commonly used in combination with chemotherapy for first and subsequent lines of therapy in follicular non-Hodgkin lymphoma (FL) and chronic lymphocytic leukemia (CLL). However, a subgroup of patients does not respond, indicating a clear unmet need to explore alternative antibodies non-cross resistant to rituximab.

Supporting Agencies


Montillo, M. (2009). Ofatumumab: a second generation anti-CD20 monoclonal antibody in chronic lymphocytic leukemia. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.583
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC